



Mitsubishi Tanabe Pharma America, Inc.
 525 Washington Blvd., Suite 400
 Jersey City, NJ 07310
 TEL 908-607-3010 FAX 201-610-1293

May 14, 2021
 Vermont Attorney General's Office
 Via Email (AGO.highcostprescriptiondrugs@vermont.gov)

RE: New Prescription Drug – 3 Day Notice

In accordance with 18 V.S.A. § 4637, Mitsubishi Tanabe Pharma America, Inc. (MTPA) hereby notifies the Vermont Attorney General of the commercial introduction of the following new NDC at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program.

18 V.S.A. § 4637 does not currently define “release of the drug in the commercial market.” Additionally, Mitsubishi is not aware of any guidance issued by the Office of the Vermont Attorney General or any applicable state regulation that defines “release of the drug in the commercial market” for the purpose of compliance with 18 V.S.A. § 4637. As a result, Mitsubishi considers “release of the drug in the commercial market” to occur upon the date of WAC Announcement which was May 12, 2021.

NDC	PRODUCT
70510-2201-02	Exservan (riluzole) oral film, 50 mg

Please do not hesitate to contact us if you have any questions.

Best Regards,

Ekaterina Miteiko

Associate Director, Financial Planning & Analytics, Operations & Strategy
 Mitsubishi Tanabe Pharma America, Inc.
 525 Washington Blvd. Ste 2620
 Jersey City, NJ 07310
[Ekaterina Miteiko@mt-pharma-us.com](mailto:Ekaterina.Miteiko@mt-pharma-us.com)
 Office: 908-607-3061 | Cell: 908-797-1126